albumin-bound paclitaxel / Generic mfg.  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

117 Trials

   Remove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
albumin-bound paclitaxel / Generic mfg.
ACTRN12624000110583: SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies

Recruiting
N/A
200
 
The University of Sydney, National Health Medical Research Council
Cancer, Cardio Vascular Disease
 
 
NCT06478355: Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma(ChinECR)

Active, not recruiting
N/A
800
RoW
Immunotherapy, PD-1/PD-L1, Chemotherapy drug, TP, radiotherapy
Hebei Medical University Fourth Hospital
ESCC
07/24
12/24
ChiCTR-IOR-17010687: Clinical study of first-line chemotherapy for ovarian cancer with paclitaxel and carboplatin albumin intravenous chemotherapy

Recruiting
N/A
100
 
Paclitaxel intravenous combined with intraperitoneal chemotherapy ;Albumin paclitaxel combined carboplatin chemotherapy
Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Shengkang hospital development center to promote the action plan of municipal hospital clinical skills and clinical disease clinical specialist three years of
ovarian cancer
 
 
NCT02318095: Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer

Completed
N/A
40
US
Gemcitabine/nab-Paclitaxel, Radiation therapy, Sugical resection, Adjuvant chemotheapy
Duke University
Resectable Pancreatic Cancers
11/18
11/22
NCT06235164: The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer

Active, not recruiting
N/A
585
RoW
immune checkpoint inhibitors: sintilimab, nivolumab, and camrelizumab
Fujian Medical University
Locally Advanced Gastric Cancer
12/22
12/25
ChiCTR-INR-17012555: Clinical study of neoadjuvant therapy used in borderline resectable pancreatic cancer

Not yet recruiting
N/A
798
 
Perform chemotherapy with mFOLFIRNOX ;Perform chemotherapy with GEM and 5-FU ; Perform chemotherapy with GEM and Abraxane
Shanghai Changzheng Hospital affiliated to Second Military Medical University; Shanghai Changzheng Hospital, Research doctor development program of Shanghai Changzheng Hospital affiliated to Second Military Medical University
pancreatic cancer
 
 
ChiCTR1900022192: Phase Ib trial for Neoadjuvant therapy with PD-1 Antibody (SHR-1210) and albumin-bound paclitaxel plus Gemcitabine on resectable/borderline resectable Pancreatic Cancer

Not yet recruiting
N/A
26
 
Neoadjuvant therapy with PD-1 Antibody(SHR-1210) and albumin-bound paclitaxel plus Gemcitabine
Chinese PLA General Hospital (301 hospital); Level of the institution:, self-funding
Pancreatic cancer
 
 
ChiCTR1900023370: Phase I clinical study for albumin paclitaxel and capecitabine chemotherapy combined with local radiotherapy for initial unresectable locally advanced gastric cancer or para-aortic lymph node metastasis

Recruiting
N/A
24
 
albumin paclitaxel and capecitabine chemotherapy combined with local radiotherapy
West China Hospital, Sichuan University; Level of the institution:, CSPC Ouyi Pharmaceutical Co.,Ltd.
Gastric cancer
 
 
ChiCTR1900023373: Phase I Clinical Study for Postoperative Early Stage Cervical Cancer with High Risk Factors Treated by Albumin Paclitaxel and Cisplatin Chemotherapy Combined with Synchronous Local Radiotherapy

Recruiting
N/A
24
 
Albumin Paclitaxel and Cisplatin Chemotherapy Combined with Synchronous Local Radiotherapy
West China Hospital, Sichuan University; Level of the institution:, CSPC OUYI PHARMACEUTICAL CO.,LTD.
Cervical cancer
 
 
HNC-SYSU-005, NCT06143761: Response to Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Oral Cancer

Completed
N/A
206
RoW
PD-1 inhibitor+carboplatin+albumin-bound paclitaxel
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Oral Cancer
06/22
06/22
ChiCTR1900027932: Pyrotinib in Combination With Albumin–Bound Paclitaxel in HER2-Positive Patients With Advanced Breast Cancer: a Multicentre Phase II Study

Recruiting
N/A
79
 
Pyrotinib in combination with Albumin–Bound Paclitaxel
Shandong Institute of Cancer Prevention and Control; Shandong Institute of Cancer Prevention and Control, artial self-expenditure
breast cancer
 
 
NCT04518800: PEG-rhG-CSF in Secondary Prevention of Nab-Paclitaxel Combined With S-1 in Advanced Pancreatic Cancer

Not yet recruiting
N/A
20
RoW
Jin Youli(PEG-rhG-CSF)
Chinese PLA General Hospital
PEG-rhG-CSF, Pancreatic Cancer
08/21
02/22
ChiCTR1900023657: A clinical trial for apatinib combination with nab-paclitaxel /cisplatin in the treatment of NSCLC

Not yet recruiting
N/A
60
 
Apatinib 250mg Po qd nab-paclitaxel: 100mg/m2 iv d1, 8, 15 cisplatin: 75mg/m2 d1 q3w, 4-6 cycles
Tangshan People's Hospital; Tangshan People's Hospital, no
non small cell lung cancer
 
 
ChiCTR1900028212: A multicenter, prospective, single-arm, exploratory clinical study of neoadjuvant therapy of her2-positive breast cancer with pyrotinib maleate tablets combined with paclitaxel for injection (albumin bound)

Recruiting
N/A
90
 
pyrotinib maleate tablets combined with albumin paclitaxel combined with epirubicin and cyclophosphamide
The First Hospital of Lanzhou University; The First Hospital of Lanzhou University, Self raise independently
breast cancer
 
 
ChiCTR1900025919: Clinical efficacy of paclitaxel albumin combined with carboplatin in neoadjuvant chemotherapy for locally advanced cervical cancer and its effect in PDX model of cervical cancer

Not yet recruiting
N/A
200
 
Albumin-bound Paclitaxel combined with Carboplatin ;Paclitaxel combined with Carboplatin
The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University, Heathco - stone cancer research foundation
cervical cancer
 
 
NCT06378840: the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer

Recruiting
N/A
20
RoW
Nab-paclitaxel/Platinum, Sintilimab
RenJi Hospital
Locally Advanced Cervical Carcinoma, Concurrent Chemoradiotherapy, Immunotherapy
12/24
12/24
PC-CURE-1, UMIN000035668: Cohort study of patients with initially unresectable pancreatic cancer in whom conversion surgery is planned after FOLFIRINOX or gemcitabine plus nab-paclitaxel therapy

Completed
N/A
360
Japan
Federation of Asian Clinical Oncology (FACO), Federation of Asian Clinical Oncology (FACO)
Unresectable pancreatic cancer
 
 
ChiCTR2000032509: Efficacy and safety of Tislelizumab plus chemotherapy as first-line treatment in elderly advanced non-small cell lung cancer

Recruiting
N/A
36
China
Tislelizumab plus chemotherapy
Jiansu Cancer Hospital ; Jiansu Cancer Hospital, self-financing
Non small cell lung cancer
 
 
ChiCTR2100045484: Nituzumab-albumin-bound paclitaxel and cisplatin therapy Single arm study of recurrent/metastatic cervical squamous cell carcinoma

Recruiting
N/A
30
 
Nituzumab treatment regimen
Baotou Tumor Hospital; Baotou Tumor Hospital, Enterprise financing
Recurrent/metastatic cervical squamous cell carcinoma
 
 
CPOG-007-A, ChiCTR1900024176: SHR- 1210 combined with Paclitaxel (Albumin Bound) and Gemcitabine as first-line therapy in patients with metastatic pancreatic cancer

Recruiting
N/A
20
 
SHR-1210, 200mg, D1; Paclitaxel (Albumin Bound), 125 mg/m2, D1, 8; Gemcitabine, 1000mg/m2, D1, 8; Every 21 days as a cycle.
Renji Hospital, School of Medicine, Shanghai Jiaotong University; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Jiangsu Hengrui Pharmaceutical Co., Ltd.
pancreatic cancer
 
 
NCT06378580: The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

Completed
N/A
72
RoW
Surufatinib combine immune checkpoint inhibitor, AG/FOLFIRINOX
Luo Cong
Pancreatic Cancer
07/23
04/24
ChiCTR2000034609: Efficacy and safety of albumin bound paclitaxel combined with pegylated liposome doxorubicin in the treatment of platinum resistant or refractory ovarian cancer: an open, single arm, phase II prospective study

Recruiting
N/A
51
 
Efficacy and safety of albumin bound paclitaxel combined with pegylated liposome doxorubicin
Shaanxi Provincial Cancer Hospital; Shaanxi Provincial Cancer Hospital, CSPC OUYI PHARMACEUTICAL CO.,LTD.
ovarian cancer
 
 
ChiCTR1900025574: An observational study for the efficacy and safety of apatinib combined with albumin-bound taxol in the second-line treatment of advanced gastric cancer

Recruiting
N/A
35
 
Apatinib combined with albumin-bound paclitaxel
The First Affiliated Hospital of Suzhou University; The First Affiliated Hospital of Suzhou University, Self financing
Gastric cancer
 
 
ChiCTR1900027332: A single-center and single-arm clinical study of neoadjuvant nab-paclitaxel combined with carboplatin therapy in patients with triple-negative or HER2-positive breast cancer

Not yet recruiting
N/A
60
 
nab-paclitaxel combined with carboplatin
West China Hospital, Sichuan University; West China Hospital, Sichuan University, CSPC Ouyi Pharmaceutical Co., Ltd.
breast cancer
 
 
ChiCTR2000038254: An exploratory study of Camrelizumab combined with nab-paclitaxel in the treatment of platinum-resistant recurrent ovarian cancer

Not yet recruiting
N/A
41
 
Camrelizumab: 200mg, iv, 30min, q2w Chemotherapy: nab-paclitaxel 80mg/m2 d1, 8, 15 iv q4w, until death or intolerable toxicity treatment
The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University, Self-financing
Ovarian cancer
 
 
NCT04603586: Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses

Recruiting
N/A
138
RoW
SBRT, Chemotherapy
Changhai Hospital
Treatment
10/22
10/23
NCT04423731: Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer

Active, not recruiting
N/A
251
Europe
Folfirinox, Gemcitabine/nab-paclitaxel, Gemcitabine, 5-FU (fluorouracil) and leucovorin, FLOX
Oslo University Hospital, Haukeland University Hospital, St. Olavs Hospital, University Hospital of North Norway, Helse Stavanger HF
Locally Advanced Pancreatic Adenocarcinoma, Chemotherapy Effect, Borderline Resectable Pancreatic Adenocarcinoma, Pancreatectomy
10/22
12/25
ChiCTR1900026622: A multicenter-center, one-arm exploratory clinical study for Apatinib mesylate combined with albumin-bound taxol in the treatment of patients with recurrent/metastatic nasopharyngeal carcinoma

Not yet recruiting
N/A
60
 
Apatinib combined with albumin-bound paclitaxel
Department of Oncology, Guigang City People’s Hospital, The Eighth Affiliated Hospital of Guangxi Medical University; Department of Oncology, Guigang City People’s Hospital, The Eighth Affiliated Hospital of Guangxi Medical University, Jiangsu hengrui co. LTD
nasopharyngeal carcinoma
 
 
ChiCTR2000037723: A prospective, randomized, double-blinded, multi-center clinical trial to evaluate the efficiency and safety of anti-PD1 antibody (Camrelizumab) combined with Paclitaxel(Albumin Bound) and Gemcitabine versus Paclitaxel(Albumin Bound) and Gemcitabine as first-line therapy in patients with metastatic pancreatic cancer

Not yet recruiting
N/A
401
 
PD-1 antibody (Camrelizumab) combined with paclitaxel (albumin- binding) and gemcitabine ;Placebo combined with paclitaxel (albumin- binding) and gemcitabine
Renji Hospital, School of Medicine, Shanghai Jiaotong University; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Jiangsu Hengrui Pharmaceutical Co., Ltd.
pancreatic cancer
 
 
ChiCTR2100044219: A prospective phase I clinical trial of paclitaxel for injection (albumin-binding) intraperitoneal perfusion combined with systemic chemotherapy for peritoneal metastasis of pancreatic cancer

Recruiting
N/A
18
 
intraperitoneal perfusion of albumin paclitaxel ;intraperitoneal perfusion of albumin paclitaxel
West China Hospital, Sichuan University; West China Hospital, Sichuan University, No
pancreatic cancer
 
 
ChiCTR2000039418: A prospective, real-world clinical study of albumin-bound paclitaxel combined with Sindilizumab in the treatment of non-small cell lung cancer

Recruiting
N/A
400
 
Immunotherapy combined with chemotherapy or chemotherapy
The Second People's Hospital of Neijiang; The Second People's Hospital of Neijiang, Wu Jieping medical foundation
Non-small cell lung cancer
 
 
ChiCTR2000039253: A single-center, randomized controlled clinical study of nab-paclitaxel combined with capecitabine versus capecitabine monotherapy for paclitaxel/docetaxel resistant advanced breast cancer

Recruiting
N/A
92
 
Paclitaxel combined with Capecitabine ;Capecitabine
Shanghai Cancer Center affiliated to Fudan University; Shanghai Cancer Center affiliated to Fudan University, CSPC Ouyi Pharmaceutical Co., Ltd.
Breast cancer
 
 
ChiCTR2100051909: Sintilimab combined with albumin-bound paclitaxel and platinum as the first-line treatment for metastatic esophageal squamous cell carcinoma: a retrospective study

Recruiting
N/A
30
 
None
He'nan Provincial People's Hospital; He'nan Provincial People's Hospital, Fund of He'nan Provincial People's Hospital 23456
esophageal squamous cell carcinoma
 
 
ChiCTR2200055659: A prospective clinical study of PD-1 inhibitor combined with albumin-paclitaxel + oxaliplatin + S-1 chemotherapy for perioperative treatment of locally advanced gastric cancer

Recruiting
N/A
30
 
Cangzhou Central Hospital; Cangzhou Central Hospital, Wu Jieping Medical Foundation
Gastric Cancer
 
 
CamPacBTC, ChiCTR2100042316: Second-line treatment of camrelizumab combined with nab-paclitaxel in advanced biliary tract cancer: an exploratory study

Recruiting
N/A
63
 
camrelizumab + nab-paclitaxel
West China Hospital of Sichuan University; West China Hospital of Sichuan University, Funds raised independently
biliary tract cancer
 
 
ChiCTR2100042236: A prospective, open-label, single arm study evaluating the efficacy of anlotinib combined with albumin-bound paclitaxel and carboplatin in neoadjuvant treatment of triple-negative breast cancer

Recruiting
N/A
53
 
Anlotinib+nab-paclitaxel+carboplatin
The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University, ChiaTai Tian Qing Pharmaceutical Company
Triple negative breast cancer
 
 
ChiCTR2200058126: II clinical study of carrelizumab, albumin paclitaxel and apatinib combined with or without Fuzi Lizhong Pill in the treatment of unresectable locally advanced/metastatic pancreatic cancer

Not yet recruiting
N/A
30
 
NA
Second People's Hospital of Anhui Province; 安徽省合肥市北二环砀山路1868号, Self-raised
pancreatic cancer
 
 
ChiCTR2100045209: Exploratory clinical study of PD-1 inhibitor combined with chemotherapy (albumin paclitaxel combined with carboplatin for three weeks) in the treatment of advanced non-small cell lung cancer

Not yet recruiting
N/A
30
 
PD-1 inhibitor + chemotherapy
The Fifth Affiliated Hospital of Sun Yat-Sen University; The Fifth Affiliated Hospital of Sun Yat sen University, self-funded
lung cancer
 
 
ChiCTR2100044498: hyperthermic intraperitoneal chemotherapy with albumin paclitaxel for the prevention of peritoneal metastasis in patients with locally advanced gastric cancer after surgery: a nonrandomized, open, multicenter study

Recruiting
N/A
30
 
intraperitoneal paclitaxel thermoperfusion chemotherapy
The Affiliated Hospital of Jiangnan University; Affiliated Hospital of Jiangnan University, self-funded
gastric cancer
 
 
ChiCTR2100046353: Neoadjuvant treatment of locally advanced resectable stage III esophageal squamous cell carcinoma with Camrelizumab combined with chemotherapy

Recruiting
N/A
60
 
Camrelizumab + albumin paclitaxel + nedaplatin
Anhui Cancer Hospital; Anhui Cancer Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd
Esophageal Squamous Cell Carcinoma
 
 
ChiCTR2000032955: Efficacy and safety of anti-PD-1 monoclonal antibody with concurrent chemoradiotherapy for potentially resectable pancreatic cancer

Recruiting
N/A
25
 
PD-1 mAb, nab-paclitaxel, gemcitabine and radiotherapy
Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital, Self-financing
Pancreatic cancer
 
 
BETTER, NCT05407155: Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer

Not yet recruiting
N/A
56
NA
bevacizumab plus nab-paclitaxel and platinum
Fudan University
Non-small Cell Lung Cancer Metastatic
06/23
06/24
NCT05132790: Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment

Active, not recruiting
N/A
24
RoW
SHR-1316 at a dose 20mg/kg q3w, SHR6390 at a dose of 150mg orally, daily, SBRT
Shengjing Hospital, Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer
12/24
12/28
ERI-Based-01, NCT05953909: A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer ().

Active, not recruiting
N/A
120
RoW
Eribulin-Based Regimen, Not Applicable since observational study, nab-paclitaxel based regimen, Other Chemotherapy Regimen
Fujian Cancer Hospital
Breast Cancer
08/23
08/23
ChiCTR2000030250: Phase II clinical trial of albumin-bound paclitaxel plus gemcitabine in the treatment of metastatic/locally unresectable soft tissue sarcoma: a single-center, open, single-arm study

Recruiting
N/A
35
 
albumin-bound paclitaxel plus gemcitabine
Department of Orthopedics, the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital; The Affiliated Cancer Hospital of Zhengzhou University, self-raised
Soft tissue sarcoma
 
 
ChiCTR2200061128: Single center, single arm, phase II clinical trial of albumin-bound paclitaxel combined with cisplatin as neoadjuvant therapy for locally advanced cervical cancer

Recruiting
N/A
50
 
albumin-bound paclitaxel combined with cisplatin
Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences, CSPC Ouyi Pharmaceutical Co., Ltd.
cervical cancer
 
 
ChiCTR2100051515: Clinical study of nituzumab combined with albumin paclitaxel combined with teggio in the treatment of locally advanced or metastatic pancreatic cancer

Not yet recruiting
N/A
33
 
No
Baotou Tumor Hospital; Baotou Tumor Hospital, Enterprise funding
pancreatic cancer
 
 
ChiCTR2100052118: Second-Line treatment of nab-paclitaxel combined with sintilimab in advanced biliary tract cancer: an exploratory study

Not yet recruiting
N/A
63
 
nab-paclitaxel + sintilimab
West China Hospital of Sichuan University; West China Hospital of Sichuan University, self-raised
biliary tract cancer
 
 
NCT05677217: Clinical Feasibility of Nab-paclitaxel Plus Gemcitabine-cisplatin Chemotherapy in Locally Advanced Cholangiocarcinoma

Recruiting
N/A
100
RoW
CHA University
Locally Advanced Cholangiocarcinoma
09/24
11/24
NCT04365049: Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma

Recruiting
N/A
100
RoW
Radiotherapy, Nab-paclitaxel, Gemcitabine, Camrelizumab
Sun Yat-sen University
PDAC - Pancreatic Ductal Adenocarcinoma
12/23
12/23
NCT05740995: Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Recruiting
N/A
40
RoW
neoadjuvant anti-PD-1 plus chemotherapy
Shanghai Zhongshan Hospital
Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy
12/23
12/28
ChiCTR2100054202: A clinic trial of PD-1 blockade combined with albumin paclitaxel and gemcitabine in the hepatic metastasis of pancreatic ductal adenocarcinoma

Not yet recruiting
N/A
40
 
Camrelizumab + Gemcitabine + albumin bound paclitaxel ;Gemcitabine + albumin bound paclitaxel
The First Affiliated Hospital of Naval Medical University, Changhai Hospital; The First Affiliated Hospital of Naval Medical University, Changhai Hospital, Suzhou Shengdia Biopharmaceutical Co., Ltd.
Hepatic metastasis of pancreatic ductal adenocarcinoma
 
 
NCT04047953: Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma

Recruiting
N/A
95
RoW
Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1, Paclitaxel (albumin-bound) + Oxaliplatin + S-1, Nab-paclitaxel + Oxaliplatin + S-1
Peking University Cancer Hospital & Institute
Gastric Adenocarcinoma
12/23
11/26
PARC, NCT04894643: Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer

Recruiting
N/A
10
Europe
Proton Ions, Nab-PACLitaxel, Abraxane®, Gemcitabine, Capecitabine, Surgical resection of the pancreas (when feasible)
EBG MedAustron GmbH, Landesklinkum Wiener Neustadt
Pancreatic Cancer, Proton Therapy
12/24
12/26
NCT04871321: Biomarker Discovery in Patients With Advanced Biliary Tract Cancer

Recruiting
N/A
120
RoW
nab-paclitaxel plus gemcitabine-cisplatin, immunohistochemistry, NGS, RNA-sequencing, Liquid biopsy
CHA University, Dong-A Pharmaceutical
Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
03/24
12/24
NCT06267144: Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer

Recruiting
N/A
20
RoW
Sintilimab plus chemotherapy
The First Hospital of Jilin University
Lung Cancer
06/25
12/25
PACsign, NCT05475366: Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures

Recruiting
N/A
62
Europe
Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC, Biomarkers of tumor signatures (translational studies)
Institut Curie
Carcinoma, Pancreatic Ductal, Prognosis
12/26
12/26
NCT05959395: Hyperthermia Treatment Added to Chemotherapy Standard of Care for Pancreatic Tumors

Recruiting
N/A
5
US
VectRx Thermal Therapy
NeoTherma Oncology, University of Maryland, Baltimore, Databean
Pancreatic Cancer
02/24
04/24
ChiCTR2000029854: Albumin Paclitaxel plus S-1 and Anlotinib as First-Line Chemotherapy for Metastatic or Unresectable Locally Advanced Biliary Tract Carcinomas: a Phase II Clinical Trial

Not yet recruiting
N/A
30
 
nab-paclitaxel plus S-1 and anlotinib
Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center; Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, self-financing
Biliary Tract Carcinomas
 
 
NCT04631445: Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer

Active, not recruiting
N/A
32
US
Ketogenic Diet
Translational Drug Development, Translational Genomics Research Institute
Metastatic Pancreatic Ductal Adenocarcinoma
12/24
04/25
NCT05378334: Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients

Recruiting
N/A
82
RoW
ICI, Chemotherapy, Placebo, Bone-protecting and Mass-dispersesing Decoction
Guangzhou University of Traditional Chinese Medicine
Non-small Cell Lung Cancer
03/24
03/25
NCT06341478: Investigator Grant (IG) 2022 27746

Recruiting
N/A
153
Europe
various neoadjuvant therapies
IRCCS San Raffaele
Bladder Cancer
03/26
03/27
NCT06349044: A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Recruiting
N/A
120
RoW
Hypofractionated radiotherapy/SBRT(5-10Gy/fx,3-5 fx), Anti-PD-1 monoclonal antibody, Oxaliplatin and Capecitabine, Anti-VEGF 15mg/kg, Anti-VEGF 7.5mg/kg, Gemcitabine and Cisplatin
Zhejiang Cancer Hospital
Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric Adenocarcinoma, Hepatocellular Carcinoma, Biliary Tract Carcinoma, Colorectal Adenocarcinoma
12/25
12/25
SMART, NCT04276857: Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer

Not yet recruiting
N/A
27
NA
Irreversible electroporation (NanoKnife® ), FOLFIRINOX (5-FU, leucovorin, irinotecan, and oxaliplatin) or gemcitabine/nab-paclitaxel
University of Saskatchewan
Locally Advanced Pancreatic Cancer, Irreversible Electroporation
03/26
03/26
NCT06494514: NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer

Recruiting
N/A
40
RoW
nal-IRI+Oxaliplatin+5-FU/LV+PD-1, Gemcitabine + albumin-paclitaxel+PD-1
Du Juan
Locally Advanced Pancreatic Cancer
04/27
04/27
ChiCTR2000031511: Efficacy and safety of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in elderly patients with locally advanced nasopharyngeal carcinoma: a prospective II phase clinical trial

Recruiting
N/A
36
 
induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy
Affiliated Cancer Hospital of Guangzhou Medical University; Affiliated Cancer Hospital of Guangzhou Medical University, Self-raised
nasopharyngeal carcinoma
 
 
NCT06417892: Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

Not yet recruiting
N/A
60
NA
PD-1inhibitor, PD-1 antibody
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastric Cancer
05/26
11/26
NCT06420908: Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)

Not yet recruiting
N/A
30
NA
Adebrelimab+TP/FP+ radiation therapy, Adebrelimab+FP/TP+ radiation therapy
Hebei Medical University Fourth Hospital
Esophageal Squamous Cell Carcinoma
05/26
05/27
ChiCTR2200061237: An exploratory clinical study of penpulimab combined with anlotinib and albumin paclitaxel in the treatment of recurrent and metastatic head and neck squamous cell carcinoma

Not yet recruiting
N/A
30
 
penpulimab combined with anlotinib and albumin paclitaxel
Qingdao Municipal Hospital East Branch; Qingdao Municipal Hospital East Branch, Beijing Kangmeng Foundation
head and neck squamous cell carcinoma
 
 
NCT03393741: Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

Terminated
N/A
5
US
Taxane, paclitaxel, nab-paclitaxel, docetaxel, Vinorelbine, vinca alkaloid, Ixabepilone, epothilone, Eribulin, halichondrins, Chemotherapy
University of Wisconsin, Madison, National Cancer Institute (NCI)
Breast Cancer, Breast Neoplasms
02/24
02/24
NCT06496724: A Clinical Study of Albumin-bound Paclitaxel/Granulocyte-based Therapy for Recurrent/Metastatic Breast Cancer

Recruiting
N/A
1
RoW
Albumin paclitaxel/neutrophil drug
JIANG LONGWEI, China Pharmaceutial University
Breast Cancer
06/25
07/25
ctDNA, NCT06103890: Dynamic Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma

Recruiting
N/A
100
RoW
Hebei Medical University Fourth Hospital, Handan Central Hospital, Xingtai People's Hospital
Esophageal Squamous Cell Carcinoma
06/24
07/25
ChiCTR2300074794: A prospective, one-arm, two-cohort clinical study of autologous γδT adoptive immune cells combined with gemcitabine-based standard first-line chemotherapy in the treatment of inoperable or metastatic biliary pancreatic malignancies

Recruiting
N/A
40
 
γδT cells+ gemcitabine+ tegafur; γδT cells+ gemcitabine+ Albumin bound paclitaxel
General Hospital of the Northern Theater Command of the Chinese People's Liberation Army; General Hospital of the Northern Theater Command of the Chinese People's Liberation Army, Liaoning Provincial Science and Technology Plan Project
Biliary pancreatic malignancy
 
 
NCT06486545: Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer

Not yet recruiting
N/A
18
NA
Irinotecan Hydrochloride Liposome Injection;Paclitaxel For Injection (Albumin Bound)
Hunan Cancer Hospital
Advanced Gastric Cancer
07/25
01/26
ChiCTR2300069581: A prospective observational study of Sulfatinib plus albumin paclitaxel and gemcitabine regimen for transformation therapy of locally advanced pancreatic cancer

Recruiting
N/A
40
 
Sofantinib combined with albumin bound paclitaxel and gemcitabine hydrochloride
The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University, self-funding
Pancreatitc cancer
 
 
CHAMP, NCT03724994: Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer

Recruiting
N/A
300
Europe
Gemcitabine, Folfirinox, Gemcitabine - nab-paclitaxel, Fluorouracil, FLOX, 5-FU, 5-Fluorouracil
Lund University
Periampullary Adenocarcinoma, Periampullary Cancer, Pancreatic Cancer
09/26
09/27
NCT06575322: Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma

Recruiting
N/A
302
RoW
Carboplatin( neoadjuvant), Paclitaxel (neoadjuvant), Anti-PD-1 Drugs, Surgical resection
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Head and Neck Squamous Cell Carcinoma
09/26
03/27
NCT02921022: Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Active, not recruiting
N/A
110
US
Gemcitabine, Nab-paclitaxel, PEGPH20
Memorial Sloan Kettering Cancer Center, Halozyme Therapeutics, Miami Cancer Institute
Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma
10/25
10/25
NCT06636591: Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer

Not yet recruiting
N/A
14
RoW
Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Epirubicin Drug: Cyclophosphamide, Device: Multimodal Tumor Thermal Therapy System Drug: SHR1316 Drug: Nab paclitaxel Drug: Carboplatin
Fudan University
Breast Cancer Female, HER2-negative Breast Cancer
02/25
10/26
EF-001, NCT06649448: A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.

Not yet recruiting
N/A
200
RoW
Efbemalenograstim alfa Injection, carboplatin/cisplatin-etoposide, Carboplatin plus Paclitaxel, Cisplatin/pemetrexed or Carboplatin/pemetrexed, TP regimen
Shandong Cancer Hospital and Institute
Solid Tumor Cancer, Chemotherapy Induced Neutropenia, G-CSF
12/25
05/26
EASOBFGE, NCT06603974: The Efficacy and Safety of Benmelstobart for GC/EGC

Not yet recruiting
N/A
48
NA
surgery, Benmelstobart, tegafur, oxaliplatin, albumin paclitaxel
Xijing Hospital
Gastric Cancer
07/26
12/26
NCT06658951: Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

Not yet recruiting
N/A
30
RoW
Anti-HER2 CAR-T cells
UTC Therapeutics Inc., The First Affiliated Hospital of Zhengzhou University
HER2-positive Advanced Malignant Solid Tumors
11/26
11/27
PPDTPC, NCT04373928: Personalized Precision Diagnosis and Treatment of Pancreatic Cancer

Recruiting
N/A
100
RoW
Drug guided by Mini-PDX/PDX, Mini-PDX/PDX
Changhai Hospital
Pancreatic Cancer
12/24
12/24
NCT05601323: A Study of Suizenji in Patients With Unresectable Pancreatic Cancer

Recruiting
N/A
90
Japan
Suizenji, Nal-IRI/FL, mFOLFIRINOX, Gem/nab-PTX
SONIRE Therapeutics Inc.
Unresectable Pancreatic Cancer
10/25
10/25
ChiCTR2400079595: Envafolimab combined with chemotherapy for preoperative neoadjuvant treatment of non-small cell lung cancer patients:a prospective, single arm, exploratory clinical study

Recruiting
N/A
25
 
During the preoperative neoadjuvant treatment period, subjects will receive 3-4 cycles of preoperative neoadjuvant treatment: Envolizumab 300mg, Q3W, subcutaneous injection; Platinum containing dual drug chemotherapy Q3W, administered on the first day of each cycle. The chemotherapy regimen should refer to the guidelines or clinical experience to choose platinum+pemetrexed/docetaxel/albumin paclitaxel/paclitaxel.Subjects underwent preoperative imaging evaluation and surgical indication evaluation 3-5 weeks after the end of their last medication before surgery. After completing 3-4 cycles of neoadjuvant therapy, subjects who still have surgical indications will undergo radical surgery with complete resection defined by NSCLC according to the World Lung Cancer Research Association standards within 4-6 weeks.
Henan Provincial People's Hospital; Henan Provincial People's Hospital, Beijing Bethune Charitable Foundation
NSCLC
 
 
NCT05653817: Advanced or Metastatic Cholangiocarcinoma

Not yet recruiting
N/A
60
NA
Carrilizumab, Albumin-bound paclitaxel, Apatinib
First Affiliated Hospital Xi'an Jiaotong University
Cholangiocarcinoma
01/25
01/26
neoTAPPL, ChiCTR2300071925: A prospective, single-arm, exploratory study of the efficacy and safety of penpulimab injection in combination with albumin paclitaxel, and carboplatin as neoadjuvant therapy for triple-negative breast cancer

Recruiting
N/A
46
 
penpulimab+albumin paclitaxel+carboplatin
Chinese People's Liberation Army Army 958 Hospital ; Chinese People's Liberation Army Army 958 Hospital, Self-raising
Triple negative breast cancer
 
 
ChiCTR2200060217: A randomized controlled study of a combination of internal and external treatments for albumin paclitaxel-related peripheral neurotoxicity

Not yet recruiting
N/A
120
 
Oral herbal group alone ;Bloodletting group alone ;Chinese medicine combined with four end bloodletting groups ;Blank control group
Shanxi Institute of Traditional Chinese Medicine; Shanxi Institute of Traditional Chinese Medicine, None
Peripheral neurotoxicity due to albumin paclitaxel
 
 
ChiCTR2300076572: Immunotherapy combined with hypofractionated SBRT, antivascular targeting and low-dose chemotherapy for the first-line treatment of non-sensitive gene mutant advanced NSCLC: An exploratory clinical study

Recruiting
N/A
42
 
SBRT, Toripalimab, Anlotinib, Albumin bound paclitaxel, probiotics, traditional Chinese medicine, GM-CSF
Fuzhou Pulmonary Hospital of Fujian; Fuzhou Pulmonary Hospital of Fujian, None
Non-small cell lung cancer
 
 
ChiCTR2300071563: A phase Ⅱ study to evaluate the efficacy and safety of Surufatinib ,Zimberelimab combined with nab-paclitaxel in advanced triple-negative breast cancer

Recruiting
N/A
29
 
Surufatinib :250mg QD P.O, , Zimberelimab :360mg I.V D1 , , nab-paclitaxel:100mg/m2 I.V D1,D8.
Provincial Hospital Affiliated to Shandong First Medical University; Provincial Hospital Affiliated to Shandong First Medical University, Self-financing
TNBC
 
 
ChiCTR2400080485: Envafolimab combined with Irinotecan or albumin-paclitaxel and Chidamide as second-line therapy in advanced and metastatic gastric cancer: A single-arm, exploratory, phase 2 trial

Recruiting
N/A
30
 
chidamide + Envafolimab + irinotecan or albumin-paclitaxel
First affiliated hospital of Soochow university; First affiliated hospital of Soochow university, self-finance
gastric cancer
 
 
ChiCTR2300077907: A prospective, single-arm clinical study of the efficacy and safety of Icaritin in combination with gemcitabine and nab-paclitaxel in patients with advanced pancreatic ductal adenocarcinoma not previously treated with systemic therapy

Recruiting
N/A
20
 
Icaritin in combination with gemcitabine and nab-paclitaxel
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Company-funded
pancreatic cancer
 
 
ChiCTR2300074055: Clinical study of zimberelimab combined with gemcitabine and albumin-paclitaxel in first-line treatment of patients with relapsed or metastatic pancreatic cancer

Recruiting
N/A
50
 
Patients will be treated with Zimberelimab combined with gemcitabine and albumin-paclitaxel. The dose of Zimberelimab was 360mg, Q3W. Gemcitabine was administrated through intravenous infusion longer than 30min at a dose of 1000mg/m2, Q3W. And dose of albumin-paclitaxel is 125mg/m2, Q3W, through intravenous infusion longer than 30min.
Shandong Provincial Hospital; Shandong Provincial Hospital, None
Recurrent or metastatic pancreatic cancer
 
 
ChiCTR2200063254: A single arm, multi-center, open lable, exploratory study of Tirelizumab combined with Nab-Paclitaxel and Gemcitabine in the treatment of patients with advanced biliary tract cancer

Not yet recruiting
N/A
30
China
Tirelizumab + Nab-Paclitaxel + Gemcitabine
Shanghai Xuhui Central Hospital ; Shanghai Xuhui Central Hospital, BeiGene (Beijing) Co., Ltd.; Qilu Pharmaceutical Co., Ltd.
biliary tract cancer
 
 
NCT06109454: Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery

Recruiting
N/A
240
RoW
Huaier granule, Z20000109(NMPA Approval Number), Control
Liaoning Tumor Hospital & Institute, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology
Non-small Cell Lung Cancer
09/25
10/28
TIP, NCT05831553: in Patients Affected by Metastatic TNBC

Recruiting
N/A
100
Europe
Tissue Immune Profile
Fondazione per la Medicina Personalizzata, University of Roma La Sapienza
Metastatic Triple-negative Breast Cancer
09/25
09/25
NCT06080620: The Choice of Treatment Methods and Efficacy of LABC

Recruiting
N/A
50
RoW
Modified radical mastectomy for breast cancer, neoadjuvant therapy, Systematic treatment
Peking Union Medical College Hospital
Locally Advanced Breast Cancer
10/25
08/26
ChiCTR2300078092: Adebrelimab combined with neoadjuvant chemotherapy in locally advanced cervical cancer

Recruiting
N/A
30
 
adebrelimab combined with albumin paclitaxel and cisplatin(Q3W, 3 Cycles)→Radical surgery
Lianyungang First People's Hospital; Lianyungang First People's Hospital, self-raised
cervical cancer
 
 
ChiCTR2300076482: An open-label, single-center, investigator-initiated, clinical study to evaluate the safety and efficacy of multi-cluster target-specific MCTL combined with AG in the therapy of advanced pancreatic cancer

Not yet recruiting
N/A
20
 
Subjects were treated with AG on days 1 and 8 of each cycle with albumin-bound paclitaxel 125mg/m2 intravenous infusion. Gemcitabine 1000mg/m2 intravenously (greater than 30min).On the first day of the first treatment cycle, blood (white blood cells >= 2.0×10^8) of the subjects were collected for the preparation of MCTL cells in the treatment cycle, and MCTL cells were induced and cultured using the detected cluster targets. MCTL cells were transfused on days 16 and 17.Cluster target-specific MCTL cells were transfused twice per treatment cycle with 100ml normal saline for re-suspension and the minimum number of transfused cells was 1×10^9, all of which were administered intravenally (no prophylactic medication was required). After the transfusion device was connected to the normal saline tube, cell transfusions were performed at a drop rate of 20-40 drops/min. If there is no special reaction after 10min, change the drop rate to 60-80 drops/min (within 30min). Gently squeeze the bottom of the transfer bag every 5-10 minutes during the return process to re-suspend the precipitated cells. The cells were rinsed with 0.9% normal saline 30-50 ml before and after transfusions, and fixed with infusion strips after transfusions.
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, The Central Government Guides Local Science and Technology Development Projects, China
pancreatic cancer
 
 
ChiCTR2400082534: A prospective, single arm, multicenter, phase II clinical study of the combination of anlotinib and albumin bound paclitaxel for second-line treatment of advanced gastric cancer

Not yet recruiting
N/A
40
 
anlotinib combined with albumin bound paclitaxel
Chizhou people's Hospital, Anhui Province; Chizhou people's Hospital, Anhui Province, Hospital subsidies and self financing
Advanced gastric cancer
 
 
 

Download Options